|
|
Post by compound26 on Nov 15, 2015 19:38:14 GMT -5
For your information, I have just added a number 8 to my original post.
8. Have someone (Al Mann, Hakan, Matt or some Afrezza uses like Sam, etc.) appear in popular shows/reports like The Oprah Winfrey Show, 60 minutes, etc.
Sanofi and Mannkind should line up with some popular shows/reports like The Oprah Winfrey Show, 60 minutes, etc. Need not be too fancy or too promotional. Just need to reveal to the world that we have this new weapon to fight against diabetes. It would be great if Al Mann himself can do it. But Hakan, Matt or some Afrezza uses like Sam will also do a great job. Just demonstrate the dreamboat and breathe a couple time would be great.
I do not think this will be that expensive and this will increase the awareness of Afrezza greatly. And I think Sanofi and Mannkind will be to line up such appearances if they take this seriously.
|
|
|
|
Post by jeremg on Nov 15, 2015 19:55:59 GMT -5
I do have one additional suggestion: Hire a freaking securities lawyer to investigate the manipulation. Matt and Hakan know this is happening and SEC has received dozens of dozens of complaints (possibly weekly!) -- light a fire under some chairs. So many folks on every message board posts facts about real-time manipulation (go to stocktwits to see screenshots happening live with GSCO screwing with price for example) --- seriously, if this kind of crap continues, why would anyone trust this market any more? let Mary Jo White and her ex-GS cronies at SEC enforcement know that citizens demand action. I'm not so sure at this point a Securities lawyer would make a difference to the eventual outcome. I already have zero faith remaining in the integrity of our markets, after MNKD comes to conclusion I will be taking these proceeds (or lack thereof) and investing in Index ETFs from here on out. GS and others are looting many small stocks before much needed regulation is implemented or retails just drop stocks entirely; they know their time is limited and are becoming more brazen in their crimes. |
|
|
|
Post by mooseybear on Nov 15, 2015 20:22:29 GMT -5
Thank you for the facts but they need to find a way to cut .At this point,with a recalcitrant partner, they need to cut immediately. Management has to forget they
are working for a one time billionaire. They're on their own now.
|
|
|
|
Post by rangersfan on Nov 15, 2015 20:32:48 GMT -5
Tom Hanks announced 2 years ago on the late show with David Letterman that he was a diabetic. If they get him on Afrezza he would go on these shows and tell everyone how great Afrezza is. Millions of people see it including doctors and the beauty is it is FREE advertising. I sent this to Matt but he never responded. What do you think?
|
|
|
|
Post by od on Nov 15, 2015 20:57:28 GMT -5
compound 26, Re: 6 and 7 - pharmaceutical marketing blocking and tackling includes understanding individual provider prescribing behavior and nuances of payor formulary placement decisions. I know some will need to suspend disbelief, but I am confident SNY is on top of the issues and committed to sooner than later resolution/progress. I share the collective disappointment in sales, but remind myself that compared to a typical pharmaceutical introduction, Afrezza was launched with almost no marketing preparation. Had SNY developed Afrezza internally a commercialization team would have been working on the launch playbook for years.
|
|
|
|
Post by robsacher on Nov 15, 2015 22:03:38 GMT -5
For your information, I have just added a number 8 to my original post. 8. Have someone (Al Mann, Hakan, Matt or some Afrezza uses like Sam, etc.) appear in popular shows/reports like The Oprah Winfrey Show, 60 minutes, etc.
Sanofi and Mannkind should line up with some popular shows/reports like The Oprah Winfrey Show, 60 minutes, etc. Need not be too fancy or too promotional. Just need to reveal to the world that we have this new weapon to fight against diabetes. It would be great if Al Mann himself can do it. But Hakan, Matt or some Afrezza uses like Sam will also do a great job. Just demonstrate the dreamboat and breathe a couple time would be great. I do not think this will be that expensive and this will increase the awareness of Afrezza greatly. And I think Sanofi and Mannkind will be to line up such appearances if they take this seriously. Please stop. Respectfully, you have no idea what management is doing and your suggestions are not helping. Let them do their jobs, please. Just because you might own some shares does not give you the right to think that top management have nothing better to do than picking up your calls. Please stop. There is much more going on of which you have no idea. Shareholders will be informed when there is proper news to be announced. Thank you. |
|
|
|
Post by mssciguy on Nov 15, 2015 22:12:59 GMT -5
I do have one additional suggestion: Hire a freaking securities lawyer to investigate the manipulation. Matt and Hakan know this is happening and SEC has received dozens of dozens of complaints (possibly weekly!) -- light a fire under some chairs. So many folks on every message board posts facts about real-time manipulation (go to stocktwits to see screenshots happening live with GSCO screwing with price for example) --- seriously, if this kind of crap continues, why would anyone trust this market any more? let Mary Jo White and her ex-GS cronies at SEC enforcement know that citizens demand action. I'm not so sure at this point a Securities lawyer would make a difference to the eventual outcome. I already have zero faith remaining in the integrity of our markets, after MNKD comes to conclusion I will be taking these proceeds (or lack thereof) and investing in Index ETFs from here on out. GS and others are looting many small stocks before much needed regulation is implemented or retails just drop stocks entirely; they know their time is limited and are becoming more brazen in their crimes. If that's really true, then the company should put itself up for sale. If the company cannot defend the share price and reputation, maybe the product and the patent portfolio would do better in the fold of a larger entity with two or more floors of corporate lawyers that specialize in defending company interests. I am beginning to get the feeling that retail investors are goldfish being thrown into a shark tank on a regular basis. The way Hakan talks about treating his employees is really cool. I would love to work for a guy like him (actually, I have had some good bosses like him). But right now, the stock and options and warrants are just fodder for Goldman's meat grinder ... it's so obvious that there is no defense. Just pony up a retainer and at least raise some eyebrows at GSCO and SEC. I have seen shorts destroy companies for profit. It's not pretty. |
|
|
|
Post by compound26 on Nov 15, 2015 22:40:15 GMT -5
For your information, I have just added a number 8 to my original post. 8. Have someone (Al Mann, Hakan, Matt or some Afrezza uses like Sam, etc.) appear in popular shows/reports like The Oprah Winfrey Show, 60 minutes, etc.
Sanofi and Mannkind should line up with some popular shows/reports like The Oprah Winfrey Show, 60 minutes, etc. Need not be too fancy or too promotional. Just need to reveal to the world that we have this new weapon to fight against diabetes. It would be great if Al Mann himself can do it. But Hakan, Matt or some Afrezza uses like Sam will also do a great job. Just demonstrate the dreamboat and breathe a couple time would be great. I do not think this will be that expensive and this will increase the awareness of Afrezza greatly. And I think Sanofi and Mannkind will be to line up such appearances if they take this seriously. Please stop. Respectfully, you have no idea what management is doing and your suggestions are not helping. Let them do their jobs, please. Just because you might own some shares does not give you the right to think that top management have nothing better to do than picking up your calls. Please stop. There is much more going on of which you have no idea. Shareholders will be informed when there is proper news to be announced. Thank you. Rob, on this I respectfully disagree. While admittedly the management must have information that you and I do not have and they may be doing a lot of things that we are uninformed of, but I do think we as shareholders do have the rights to communicate our thoughts to them. And I am not saying any hatred words or blaming them for anything. Members here see that I am not a basher or anything like that. Previously I have never thought about writing to the management. However, on 11 November 2015, when a rumor was circulated around the web that Mannkind’s Israel offering will be cancelled, our PPS dropped another 20% to $1.76. On this particular forum, you and I personally saw messages coming in that quite a few long term holders of Mannkind that you and I knew were either forced to sell out for a loss or got so disappointed at the situation that they sold out and gave up. What a shame! Not meant to be dramatic or anything, however, when our cash balance is reduced to $32.9 million and a rumor of failed Israel offering was able to drive down our PPS to around $1.76, the management should take an awakening call and realize that a financial war has been declared against us. I do not have any doubt that Mannkind will survive and do well over time. But now is the time to roll up our sleeves and take some decisive actions. It is like Buffett has said (the financial crisis was like Pearl Harbor or Sept. 11, when those things hit, a war is to be declared). Now is the time for the management to take action decisively and step up to be the great leaders. I respect the management, but they made mistakes in not raising money when our shares were at $11, $7 or even $5. Now we have to raise money at around $2. As JPG has pointed out, it is general practice for biotech firms to offer shares at high waters. If you look at EXAS, their shares recently traded at $7 (now probably around $9), but they raised capital when they were trading at around $25. EXAS at this moment has a similar market cap to Mannkind (their current market cap is around $900 million) and they do not have a big pharma partner like we do. But when I last checked, they have around $343 million cash to support they ramp up of Cologuard as of the last quarter ( finance.yahoo.com/q/ks?s=EXAS+Key+Statistics). Their annual cash burn is around $130 million. So their existing cash is enough to support 2.6 years. On the other hand, we have a billionaire founder and a big pharma partner and our last quarter cash balance is $32.9 million. If we just did the same thing as what EXAS did, for example, issuing 50 million shares around $7 or even $6 earlier this year, we would have around $300-350 million on the balance sheet. What would our PPS be today? And would we still have those shorts claiming Mannkind is on the brink of bankruptcy on a daily basis? In the end, I still trust our management, but they need to wake up and do some long term financial planning and clean-up. We are currently living on a quarter-by-quarter basis. If Matt is claiming that the retail investors loaning their shares (I by the ways do not loan out any of my shares) are helping the shorts, the management by not securing sufficient long term financing, is helping the shorts to a greater extent.I am not blaming the management for the slow ramp-up of Afrezza, for which they probably doesn't have much say or control. But Mannkind's own financing is to a much greater extent in their hands. Granted, they may not have been given the best hand (like in a poker game), but they still can plan and form a long term strategy to strive for the best outcome. If I am the unwelcome messenger that delivers the awakening news to the management. That's fine with me. Additionally, those are only my suggestions. Granted, many of these suggestions may not be practical or correct. But can you say none of the suggestions are reasonable or practical? The management can read these suggestions and they need not follow my suggestions. But good management does value listening to and communicating with shareholders, just like Buffett and Munger still do. In their 80s and 90s, each year in their annual meeting, they still spend hours listening to and answering shareholders' questions and suggestions and they do not think it is a waste of time. |
|
|
|
Post by ryanwal26 on Nov 15, 2015 22:40:44 GMT -5
Another suggestion would be to lay out exactly what has to happen in order to receive the milestone payments.
|
|
|
|
Post by tbone on Nov 16, 2015 0:27:09 GMT -5
all of this is good but can anyone explain why we need to be burning thru 10 to 12 million a month? How much is related to a product were not selling very much of at this time? I think at this rate if we don't raise money (and dilute if necessary ) soon we will be sold for pennies a share. Ive held 50K shares for 7 years btw. According to Mannkind press release, in the last quarter, it is around $6.3 million R&D, $11.5 million in G&A and $8.1 million in manufacturing related costs and expenses. In total, around $ 25/26 million per quarter and in line with what Matt says about $8-10 million per month. So probably $100-120 million per year. It appears they probably can not cut much more on that. Is the sad truth that we still burn closer to $45M/quarter? We just have 1/3 of it put on a credit card with Sanofi and don't show it?? |
|
|
|
Post by doodyfree on Nov 16, 2015 0:37:19 GMT -5
please read the 10q to understand the cash burn and what is charged to jac. burn is ~30s not 40s
|
|
|
|
Post by jpg on Nov 16, 2015 0:53:55 GMT -5
Please stop. Respectfully, you have no idea what management is doing and your suggestions are not helping. Let them do their jobs, please. Just because you might own some shares does not give you the right to think that top management have nothing better to do than picking up your calls. Please stop. There is much more going on of which you have no idea. Shareholders will be informed when there is proper news to be announced. Thank you. I respect the management, but they made mistakes in not raising money when our shares were at $11, $7 or even $5. Now we have to raise money at around $2. As JPG has pointed out, it is general practice for biotech firms to offer shares at high waters. If you look at EXAS, their shares recently traded at $7 (now probably around $9), but they raised capital when they were trading at around $25. EXAS at this moment has a similar market cap to Mannkind (their current market cap is around $900 million) and they do not have a big pharma partner like we do. But when I last checked, they have around $343 million cash to support they ramp up of Cologuard as of the last quarter ( finance.yahoo.com/q/ks?s=EXAS+Key+Statistics). Their annual cash burn is around $130 million. So their existing cash is enough to support 2.6 years. On the other hand, we have a billionaire founder and a big pharma partner and our last quarter cash balance is $32.9 million. If we just did the same thing as what EXAS did, for example, issuing 50 million shares around $7 or even $6 earlier this year, we would have around $300-350 million on the balance sheet. What would our PPS be today? And would we still have those shorts claiming Mannkind is on the brink of bankruptcy on a daily basis? I so agree on this crucial point. Most well run biotechs tend to do exactly that. Raise capital when the share price is high. Coincidentally (or not...) those who survive seem to do this! Do you think Exact would still be a going concern (and have any value) if it had a few months of cash left? Like I previously said I was expecting a capital raise when the share price was double digits and was very surprised to not see it happen. To be again boringly repetitive I thought at the time this was 'one smart company that knew great things were 'guaranteed' just around the corner'... Hmmm... How did that turn out? The 'floor price conversion thing' came next. Then the gasping for fiancil survival with the Israeli listing. Retrospectively not raising cash at a higher share price was such an amateurish mistake that it begs to be asked what other amateurish mistakes lie in store for Mannkind? The thing is we didn't have access to all the info while management did. With the info they had how could they not have thought there would soon be a risk of there being a cash crunch? Blindly trusting management might be hazardous to your wealth? To get my confidence back they have some good execution and salesmanship to do. |
|
|
|
Post by jpg on Nov 16, 2015 0:54:53 GMT -5
please read the 10q to understand the cash burn and what is charged to jac. burn is ~30s not 40s Tbone is right. The 'hidden' difference is, like he says, put on the Sanofi credit card. |
|
|
|
Post by doodyfree on Nov 16, 2015 2:11:57 GMT -5
As I have mentioned, actual cash burn is ~30m. Costs from the joint afrezza venture has always applied to the SNY credit line. Its the purpose of the credit line, and that cost scales based on how well afrezza does on the market.
The only burn rate that's interesting at this point is the cash burn which is ~30m a quarter. To imply otherwise is misleading.
|
|
|
|
Post by doodyfree on Nov 16, 2015 2:14:08 GMT -5
Also, there's nothing "hidden". All is on the 10Q.
|
|
